Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for severe brain clots: clot removal plus meds vs. meds alone

NCT ID NCT07548346

Disease control Sponsor: Middle East North Africa Stroke and Interventional Neurotherapies Organization Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether removing blood clots from brain veins (endovascular thrombectomy) plus standard blood thinners works better than blood thinners alone for people with severe cerebral venous sinus thrombosis (CVST). The trial will include 440 adults at high risk of poor outcomes. The main goal is to see if the procedure helps more people live independently after 12 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 440 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-65 years, inclusive * Radiologically confirmed cerebral venous sinus thrombosis (CVST) by CT venography (CTV), MR venography (MRV), or digital subtraction angiography (DSA), with thrombosis of at least one major dural sinus * Acute or subacute presentation with symptom onset within 21 days of randomization * MRI phase characterization confirming acute or subacute phase * At least one risk factor for poor outcome: symptoms of intracranial hypertension (severe headache, papilledema, visual obscurations), focal neurological deficit, seizures, altered consciousness (GCS 9-14), intracranial hemorrhage from venous congestion, or deep venous system thrombosis * Significant venous outflow obstruction on imaging * Written informed consent from patient or legally authorized representative Exclusion Criteria: * Isolated cortical vein thrombosis without dural sinus involvement * Isolated cavernous sinus thrombosis * Chronic-phase CVST on MRI phase characterization * Pre-morbid modified Rankin Scale (mRS) score greater than 2 * Glasgow Coma Scale (GCS) score less than 9 at randomization * Imminent risk of transtentorial herniation requiring emergent decompressive craniectomy * Massive cerebral edema with midline shift greater than 10 mm requiring surgical intervention * Active systemic bleeding or hemorrhagic diathesis * Severe allergy to iodinated contrast media * CVST secondary to active hematological malignancy or life expectancy less than 12 months * Pregnancy * Participation in another interventional clinical trial within 30 days * Any condition rendering the patient unsuitable for study participation per investigator judgment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral venous sinus thrombosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral sinovenous thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebral venous sinus thrombosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites in 8 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aga Khan University

    Karachi, Pakistan

  • Ain Shams University

    Cairo, Egypt

  • Alexandria University, Smouha Comprehensive Stroke Center

    Alexandria, Egypt

  • Amman Specialized IR Center

    Amman, Jordan

  • Cairo University

    Cairo, Egypt

  • Centre Hospitalier Universitaire Ibn Sina de Rabat

    Rabat, Morocco

  • Department of Neurology, Eskisehir Osmangazi University

    Eskişehir, Turkey (Türkiye)

  • Institut National de Neurologie

    Tunis, Tunisia

  • King Abdulaziz Medical City

    Jeddah, Saudi Arabia

  • King Abdullah Medical City

    Mecca, Saudi Arabia

  • King Khalid University

    Abhā, Saudi Arabia

  • Neurology Department, Al-Azhar University

    Cairo, Egypt

  • Neurology Department, Dr. Lutfi Kirdar City Hospital

    Istanbul, Turkey (Türkiye)

  • Weill Cornell Medicine-Qatar

    Doha, Qatar

More trials for these conditions

Other studies related to the condition(s) this trial covers.